Icon Energy Corp. Reports Financial Results for the Year Ended December 31, 2024, and Declares Cash Dividend of $0.07 per Common Share

Iconic Labs PLC (LSE:ICON) said it received a valid conversion notice dated 1 June 2026. One convertible note will convert into 458,716 ordinary shares at GBP 0.0109 per share, for an aggregate principal of GBP 5,000. Application has been made for admission to LSE Main Market, expected around 8 June 2026. Issued share capital will total 16,039,907 shares.

Jefferies Financial Group Inc. is in dispute with Glencore Plc over $526.4 million in overdue payments linked to Radiant World, an iron ore trader. Jefferies claims Glencore owes the amount, while Glencore denies any obligation. Emails show escalating tensions as Jefferies seeks information on invoices, with Glencore alleging Radiant World was involved in fraud. Radiant World and Sapphire Minmetals have filed a $2 billion lawsuit against Glencore, which denies the claims.

Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight, citing concerns over semaglutide's patent expiration and its impact on revenue. The stock, trading at 10.6x earnings, fell 2% post-call. Analysts debate whether the multiple reflects a bargain or undervalues future growth. Hedge funds increased holdings, while short interest remains low.

Halliburton (HAL) secured a multi-year contract from Eni (E) for the Cronos ultra-deepwater project in Cyprus, covering integrated drilling and well services. The deal aims to boost revenue per well and improve operational efficiency, though profitability depends on pricing and delivery costs. HAL's Q2 Europe/Africa revenue rose 19% sequentially, partly driven by regional activity.

Baird downgraded NIKE (NKE), Dick's (DKS), adidas, Rocky Brands, and VF Corp to Neutral, citing consumer spending concerns due to oil prices and interest rates. NIKE and DKS are interconnected, with NIKE products making up 31% of DKS's merchandise. DKS shares fell 30% in August after lowering full-year expectations. Hedge fund holdings in DKS increased, while NIKE saw a decline. Baird's report suggests potential structural demand weakness in the footwear segment.

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.